S&P Futures
4,048.25 -36.00 (-0.88%) Dow Futures
33,839.00 -207.00 (-0.61%) Nasdaq Futures
12,077.75 -144.50 (-1.18%) Russell 2000 Futures
1,901.70 -17.80 (-0.93%) Crude Oil
79.72 +0.04 (+0.05%) Gold
1,941.70 -3.90 (-0.20%)
Thorne HealthTech, Inc. (THRN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.1500 |
| Open | 4.1300 |
| Bid | 3.8800 x 1400 |
| Ask | 7.1000 x 1300 |
| Day's Range | 4.0900 - 4.5400 |
| 52 Week Range | 3.4100 - 7.3800 |
| Volume | |
| Avg. Volume | 78,618 |
| Market Cap | 239.089M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 27.94 |
| EPS (TTM) | 0.1600 |
| Earnings Date | Nov 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.90 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for THRN
Related Research
- Thorne Healthtech, Inc.Daily – Vickers Top Buyers & Sellers for 06/17/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat7 months agoArgus Research
- Insider Monkey
13 Cheap New Stocks To Buy
In this article, we will take a look at the 13 cheap new stocks to buy. To see more such companies, go directly to 5 Cheap New Stocks To Buy. Global markets were rattled by the market crash of 2022 whose reverberations are expected to affect equities for several months to come. However, prudent investors […]
- Simply Wall St.
While individual investors own 18% of Thorne HealthTech, Inc. (NASDAQ:THRN), public companies are its largest shareholders with 59% ownership
Every investor in Thorne HealthTech, Inc. ( NASDAQ:THRN ) should be aware of the most powerful shareholder groups. The...
- PR Newswire
U.S. Appeals Court Issues Final Ruling That Upholds Thorne HealthTech Inc.'s Prior Challenge of Nicotinamide Riboside Intellectual Property Claim
On January 3, 2023, the U.S. Circuit Court of Appeals for the Federal Circuit in Washington, D.C., issued a final ruling rendering the previously issued U.S. Patent No. 8,383,086 ("the '086 patent") to be unpatentable and therefore invalid. The '086 patent claim covered "The pharmaceutical composition . . . wherein nicotinamide riboside is isolated from a natural or synthetic source." The effect of the '086 patent was to provide broad patent protection of the nicotinamide riboside (NR) molecule
